Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that nano-transferosomal gel formulations of finasteride improved its delivery across skin layers, potentially reducing major side effects associated with oral administration for treating male pattern baldness.

In this study, Polygonum multiflorum Radix promoted hair growth in mice, with oral administration being more effective, likely through FGF-7, while topical application favored SHH-related mechanisms.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This review discusses post-SSRI sexual dysfunction syndrome and highlights its significant clinical and regulatory implications, but reports no new findings.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This study found that surface-modified liquid crystalline nanoparticles significantly enhanced skin permeation of finasteride and dutasteride compared to unmodified nanoparticles, suggesting potential for improved treatment efficacy in androgenetic alopecia.

This study found that finasteride maintained chemical and physical stability in various excipient mixtures, which may guide the development of stable topical delivery systems.

This review covers the diagnosis of polycystic ovary syndrome and the management of related infertility, describing evaluation and initial treatment steps, without presenting new clinical results.

This article reviews ongoing concerns about the safety of 5α-reductase inhibitors like finasteride, highlighting the lack of long-term data on persistent depression and sexual side effects after drug discontinuation; no new clinical results are reported.

In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.

This report describes a case where a man developed reversible myalgia and significant hyperCKemia after long-term finasteride use for male frontal baldness, with symptoms resolving upon discontinuation.

This article examines 5 alpha-reductase inhibitors and their link to persistent sexual dysfunction, but it reports no new clinical findings.

This study found that Italian dermatologists commonly prescribe 1 mg/day finasteride for androgenetic alopecia despite reported sexual side effects, due to its perceived long-term efficacy.

This study found that finasteride may reduce inappropriate sexual behaviors in geriatric patients with vascular dementia and benign prostate hyperplasia without serious side effects, though some patients required additional medications.

This study developed finasteride-containing granules using a method that improved follicular targeting for androgenic alopecia and reported potential for easy industrial production.

Finasteride for female hair loss has low side effects, more research needed.

This study found that men with androgenetic alopecia at age 20 years may have a higher risk of developing aggressive prostate cancer, particularly advanced stage disease.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This study suggests that continuing finasteride therapy after mastectomy does not significantly affect gynecomastia recurrence in men taking finasteride for alopecia.

Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.

Keith Kaufman reported promising results on treating male-pattern baldness with oral finasteride at the World Congress of Dermatology.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

Finasteride can cause low platelet count in rare cases.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

This review discusses techniques for harvesting follicular units, medical treatments for androgenetic alopecia, and potential future advancements in hair restoration therapy, but it reports no new clinical results.

Finasteride's sexual side effects may be due to nocebo effect.

This study suggests that a newly discovered protein, AMY117, found in Alzheimer's disease brain lesions may be crucial in the disease's development and progression.

This case report documented a 32-year-old man's acute pancreatitis following an overdose of finasteride, highlighting the potential for rare but severe side effects from the drug in overdose situations, and suggesting a need for further research into its safety.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.